Page 174 - Eceptor News Today

A new study has focused on the genomic profile and early transmission dynamics of Omicron. This study revealed the dominance of the Omicron variant in regions with high levels of population immunity.

A new preprint research paper posted to the bioRxiv* server examines the nature and effects of the spike mutations and identifies a vulnerable point that could help develop broad-spectrum protection against circulating variants.

The study assesses the degree to which the D614G mutation in the SARS-CoV-2 RBD allows access of spike protein trimers to LA-binding-like conformations.

A new study proposes a multi-boost vaccine strategy with a longer duration between the second and third dose, as that would be beneficial in acquiring immunity against severely mutated SARS-CoV-2 variants.

A new study shows that although the Omicron variant exhibits significant immune escape compared to other SARS-CoV-2 variants, antibody neutralization can be largely restored with booster doses of mRNA vaccines.

Researchers determine whether SARS-CoV-2 could cross the blood-testis barrier and be detected in human semen after infection.

New study results highlight that Omicron has an increased affinity to ACE-2 receptors, therefore, has increased infectivity, viral load, and transmissibility compared to other variants of concern, including the Delta variant.

A new study posted to the bioRxiv* preprint server aimed to demonstrate whether the loss of the QTQTN motif attenuates SARS-CoV-2 replication in respiratory cells in vitro and pathogenesis in hamsters.

Helsinn Group Announces European Medicines Agency's (EMA) Acceptance for review of the Marketing Authorization Application (MAA) for Infigratinib for Patients with Cholangiocarcinoma with

Researchers discuss the sensitivity of the SARS-CoV-2 Omicron variant towards various monoclonal antibodies.